Background/Aims: Rap1 interacting factor 1 (RIF1) was deemed to be involved in replication timing regulation and DNA damage response. However, little is known about the role of RIF1 in malignancies. Thus, this study aimed to investigate whether the expression of RIF1 is relevant to the response of epithelial ovarian cancer (EOC) patients to cisplatin chemotherapy and its underlying mechanism. Methods: Immunohistochemistry was used for detecting the expression of RIF1 in 72 human ovarian cancer tissues followed by association analysis of RIF1 expression with patients' responses to platinum-based chemotherapy. The survival analysis of ovarian patients based on platinum chemotherapy was analyzed using online databases. RNA interference of RIF1 was carried out in OVCAR3 and A2780 cell lines, to determine the effect of lacking RIF1 expression on cellular responses to cisplatin by using MTS assay. The nucleotide excision repair (NER) capacity of these cells was assessed by using host-cell reactivation and UV sensitivity assay. Western Blot analysis was carried out to determine the effect of RIF1 on the proteins of NER and apoptosis signaling pathway by using RIF1 knockdown cells. BALB/c nude mice model was used for detection of response to cisplatin in vivo. Results: RIF1 expression was significantly associated with the response of ovarian patients to platinum-based chemotherapy (P<0.01). In cohorts from online databases, high RIF1 plays an important role in regulating the expression of NER proteins, which in turn contributes to cellular response to cisplatin and EOC patients' response to platinum-based chemotherapy. RIF1 knockdown also promotes cisplatin-induced apoptosis. RIF1 may serve as a novel biomarker for predicting platinum-based chemosensitivity and the prognosis of EOC patients.
Introduction
Epithelial ovarian cancer (EOC) remains to be the most prevalent gynecologic malignancies as well as the fifth leading cause of death by cancer among women in the United States [1] . Most EOC patients are diagnosed at advanced phase of disease, and the overall five-year survival rate is relatively low [2] . The standard first-line treatment for EOC is primarily cytoreductive surgery (CRS) followed by platinum-based chemotherapy [3] . However, the efficacy of chemotherapy is limited, for approximately 25% of patients relapse within six months and the overall five-year survival rate is about 30% [4] . Therefore, it's imperative to find useful clinical markers to predict chemosensitivity of cisplatin in EOC and to decrease the failure of chemotherapy.
Platinum analogues induce DNA damage by binding to DNA in target cells, promoting apoptosis and leading to the anti-neoplastic activity [5] [6] [7] [8] [9] . One of the main mechanisms of platinum resistance is DNA repair [10] . Furthermore, nucleotide excision repair (NER) mechanism is the most primary way to repair DNA damages induced by platinum analogues among the several known DNA repair pathways [11] [12] [13] . Excision repair cross-complementation group 1 (ERCC1), replication protein A (RPA) and xeroderma pigmentosum complementation group A (XPA) protein all play important roles in NER pathway [11, [14] [15] [16] . Besides, increased NER proteins expression level is related to platinum-based chemoresistance in many cancers, including EOC [17] [18] [19] [20] [21] [22] [23] and suppressed NER proteins improves ovarian cancer patients' response to cisplatin-based chemotherapy [24] . Nevertheless, the underlying mechanism of increased NER proteins level in platinumbased chemoresistance cancers has not been disclosed yet.
Rap1 interacting factor 1 (RIF1) was firstly identified in Saccharomyces cerevisiae in 1992, which is crucial for the maintenance of telomere length [25] . In mammalian cells, RIF1 mainly participated in replication timing regulation and DNA damage response [26] [27] [28] [29] . RIF1 was reported to participate in DNA double-strand break (DSB) repair by acting as the downstream of ATM/53BP1 in human cells [30, 31] . However, whether RIF1 is involved in NER pathway remains unexplored.
Interestingly, it's indicated that the expression level of RIF1 was obviously higher in human breast tumors than those in benign lesions. Besides, silencing of RIF1 sensitizes MCF7 cells to camptothecin (CPT) or staurosporine treatment [32] . Yet, little is known about the role of RIF1 in cancer chemosensitivity and the character of RIF1 in EOC patients.
In this study, we investigated the role of RIF1 in platinum-based chemotherapy in EOC treatments and explored the underlying mechanisms. We found that RIF1 expression correlated with the chemosensitivity of EOC patients to platinum-based chemotherapy. Knockdown of RIF1 expression increased the cellular sensitivity to cisplatin in vitro and in vivo. Further investigation revealed that RIF1 knockdown enhanced the activation of cisplatin-induced apoptosis signaling. Moreover, RIF1 mediated cellular NER activity by regulating the NER proteins expression, which in turn affected the cellular chemosensitivity to cisplatin.
Immunohistochemistry
All tissue specimens were collected via biopsy of paraffin-embedded samples for immunohistochemistry (IHC) analysis in the Pathology Department of Xiangya Hospital or Hunan Provincial Tumor Hospital. Tissue sections (4 μm thick) were cut from paraffin embedded blocks. The tumor sections on slides were baked at 60°C for 30 minutes followed by incubation in xylene for 3 x 10 minutes and rehydration through graded ethanol to distilled water. Antigen retrieval was done by heating samples in 1 mmol/L EDTA for 20 minutes. Nonspecific staining was blocked by 10% goat serum in PBS buffer for 20 minutes at room temperature. The endogenous peroxidase activity was quenched by incubation in 3% H 2 O 2 for 10 minutes. And then the slides were incubated with rabbit polyclonal monospecific RIF1 antibody or PBS control at 4°C overnight followed by incubation with biotinylated goat anti-rabbit antibody and peroxidase-conjugated streptavidin. The 3, 3'-diaminobenzidine tetrahydrochloride substrate kit (Zhongshan Goldenbridge) was used to visualize staining according to the manufacturer's instructions and the hematoxylin and eosin were used to counterstain all samples before viewing with a Leica DMI 4000B inverted microscope.
All ovarian cancer tissue sections were reviewed by two experienced pathologists and staining of RIF1 was independently scored by two pathologists blinded to the clinical data using the semiquantitative immunoreactive score (IRS) system. The score of the RIF1 staining intensity were performed as previously described [36] . The percentage of RIF1-positive cells was scored as follows: < 25% = 1, ≥ 25% to 50% = 2, ≥ 50% to 75% = 3, and ≥ 75% to 100% = 4. The staining intensity was scored as follows: negative = 0, weak = 1, moderate = 2, and strong = 3. A final IRS score was then calculated by multiplying these two scores. The cut-off score was set to 4.0 according to receiver operating characteristic curves (ROC) analysis. If the final score was < 4, the tumor was considered to have low RIF1 expression; whereas the score ≥ 4 indicated high RIF1 expression. Two siRNA sequences targeting human RIF1 cDNA were synthesized by GenePharma: RIF1 KD1: 5'-GCCUUUGAGUUCCAUCCAUTT-3', KD2: 5'-GGUCAUACCUUUAGUGGUUTT-3'. The targeting sequence of scrambled control of siRNA was 5'-UUCUCCGAACGUGUCACGUTT-3'. Lentiviral vectors pGLV3/H1/GFP were acquired from GenePharma. The sequence of 5'-TTCTCCGAACGTGTCACGT-3' was used to generate lentivirus expressing shRNA targeting human RIF1, viral infection was performed according to the direction for use provided by GenePharma. RIF1 stable knockdown OVCAR3 cell lines were screened out over 15 days with 2 μg/ml puromycin. The western blot analysis and real-time reverse transcriptase PCR were performed after 30 generations of cell culture to verify the stable knockdown of RIF1 in OVCAR3 cell lines.
Survival assay
Cell viability was detected by MTS approach according to the protocol for Cell Titer 96 Aqueous-OneSolution Cell Proliferation Assay kit (MTS). RIF1 knockdown cells were seeded in 96-well plates at a density of 5 × 10 3 cells in 100 μL medium and incubated with cisplatin (Sigma) for 24 hours. The medium was then replaced by 100 µL MTS and RPMI-1640 media with a ratio of 1:9. Cell viability was then obtained by measuring the absorbance at a wavelength of 490 nm. All experiments were performed at least three times. The IC 50 was calculated from the dose-response curves using GraphPad Prism 5.0 program (GraphPad Software, Inc.)
Real-time reverse transcriptase PCR Total RNA was isolated from cultured cells by TRIzol reagent (Invitrogen). Reverse transcription was performed using PrimeScript RT reagent Kit With gDNA Eraser (TaKaRa), and the quantitative RT-PCR was performed using SYBR Premix DimerEraser (Perfect Real Time) kit (TaKaRa Bio Inc) on the Roche LightCycler480 (Roche). The primers used are listed in Table 1 . Data were analyzed using the -2 ∆∆ct method and the expression of β-actin was used as normalization control.
Western blotting
Western blotting was carried out as described previously [37] . In brief, for Western blotting, proteins were extracted using RIPA buffer mixed with protease inhibitors (1:100), phenylmethylsulfonylfluoride (PMSF, 1:100) and dithiothreitol (DTT, 1:100) at 4°C for 30 minutes. The lysate was centrifuged at 13000 rpm at 4°C for 15 min. The supernatants were collected and protein concentrations were measured using the BCA method. For Western blot analysis, protein samples were separated by 8% SDS-PAGE and transferred onto polyvinylidene difluoride membranes (Bio-Rad). The membranes were then blocked with 5% nonfat milk and incubated with primary antibodies overnight followed by washing and reaction with horseradish peroxidase-conjugated secondary antibody for 1 hour at 37°C. The reaction was detected by using ECL reagents (GE Healthcare) and the signals were captured by X-ray films. The GAPDH or β-actin were used as normalization control.
Host-cell reactivation assay
The firefly luciferase assay-based host cell reactivation (HCR) assay was implemented as previously described [38] . In brief, the pCMVluc plasmid (178 ng/μL) in a 96-well plate was UV irradiated (254 nm) on ice by a Stratalinker UV Crosslinker (Stratagene). UV-induced damages were validated by using PCR [39] with a forward primer of 5'-CGGTATCTTATCATGTCTG-3' and a reverse primer of 5'-TGCTTCTGACACAACAGT-3'. The UV-damaged or unirradiated control plasmids (0.4 μg) were transfected to 5 x 10 4 cells in a 24-well plate by using Lipofectamine 2000 (Invitrogen). A pRL-TK (Promega) plasmid encoding renilla luciferase was taken as a control for transfection 
UV sensitivity assay
The UV sensitivity assay was carried out as previous study with amendment [40] . On the one hand, the OVCAR3 cells were irradiated with UV (254 nm，0, 5 or 10 J/m 2 ) or not in 96-well plates and incubated in fresh media. After 24 h of recovery, the cell viability was detected by MTS approach as stated above. On the other hand, the OVCAR3 cells were UV irradiated (10 J/m 2 ) or not in 96-well plates, incubated in fresh media, and then the cell viability was detected at various repair time points (0, 24 and 48 h) by MTS approach. All experiments were performed at least three times. The XPA-suppressed OVCAR3 cells was used as NER-deficient control.
Animal studies
All animal care and experimental procedures were carried out according to the National Institutes of Health's Guide for the Use and Care of Laboratory Animals, and were approved by the Institutional Review Board of Central South University (Changsha, China). Female BALB/c nude mice (4 weeks of age, 18-22 g) were obtained from Shanghai SIPPR -B&K Laboratory Animal Corp. Ltd., and fed under specific pathogenfree conditions at Department of Laboratory Animals, Central South University. In order to initiate tumors, 2×10 6 scrambled control and RIF1 stable knockdown OVCAR3 cells were inoculated subcutaneously into each flanks of nude mice. The cisplatin was administered at a dose of 5 mg/kg every 4 days by intraperitoneal injection while the tumors were measurable. The tumors were examined every 4 days, maximum (L) and minimum (W) length of the tumor were measured with calipers, and the tumor volumes were calculated as 0.5LW 2 . On day 24, the animals were euthanized and the tumors were excised and weighed.
Statistical analysis All data were described as mean ± standard deviation (SD). For comparison of differences between groups, Pearson's χ 2 test or Fisher's exact test were used for qualitative variables, Student's t test or analysis of variance (ANOVA) were used for continuous variables. Survival curves were graphed using the KaplanMeier method, and the groups were compared using log-rank test. Statistical analysis was conducted using SPSS 18.0 (SPSS Inc.). P≤0.05 was considered statistically significant.
Results

Upregulation of RIF1 correlates with poor prognosis in EOC
To investigate the relationship between RIF1 expression and EOC prognosis, we screened out the data of ovarian cancer patients who received platinum-base treatment from the Kaplan-Meier plotter database (http://kmplot.com/analysis/). Kaplan-Meier survival curves and log-rank test survival analysis demonstrated that overexpression of RIF1 mRNA level was associated with worse overall survival (OS) of EOC patients (RIF1 low vs high expression patients: hazard ratio [HR] of survival = 1.24, 95% confidence interval [CI] = 1.08 to 1.43, P <0.01) (Fig. 1A) . Besides, overexpression of RIF1 mRNA level was also associated with worse progress free survival (PFS) of EOC patients (RIF1 low vs high expression (Fig. 1B) . These results indicated that high expression of RIF1 was associated with higher mortality of EOC patients with platinum-based chemotherapy.
Correlation of RIF1 expression with chemosensitivity
The RIF1 protein expression level in tissues of EOC patients was firstly evaluated by IHC (Fig. 1C) . Then, we analyzed the association of RIF1 expression with chemosensitivity and the results were summarized in Table 2 . RIF1 staining did not appear to have any statistically significant correlation with age, histologic type and histodifferentiation which were listed in the table. However, RIF1 staining had significant correlation with chemosensitivity of platinum-base treatment and FIGO Stage (P = 0.002 and P = 0.001, respectively). In general, chemotherapy resistant patients had higher RIF1 expression. Approximately 65.8% chemoresistant EOC patients of platinum-based treatment had high RIF1 level, these numbers went down to 34.2% for chemosensitive EOC patients of platinum-based treatment. Thus, the level of RIF1 expression correlated with chemosensitivity of EOC patients and the increased RIF1 expression level may increase chemoresistance. The data were obtained from Kaplan-Meier plotter database and all plots were analyzed by combing 15 data sets (GSE14764: n = 80, GSE15622: n = 35, GSE18520: n = 63, GSE19829: n = 28, GSE23544: n = 28, GSE26193: n = 107, GSE26712: n = 195, GSE27651: n = 49, GSE30161: n = 58, GSE3149: n = 116, GSE51373: n = 28, GSE63855: n = 101, GSE65986: n = 55, GSE9891: n = 55,and TCGA: n = 565). (C) Representative IHC staining of RIF1 expression in human ovarian tumor tissues. H&E: representative hematoxylin and eosin staining in ovarian cancer tissues. Sensitive: representative specimens of RIF1 staining of the patient sensitive to platinum. Resistant: representative specimens of RIF1 staining of the patient resistant to platinum. HR = hazard ratio. 
Silencing of RIF1 expression in EOC cells by siRNAs and established RIF1 stable knockdown cell lines
To investigate the functional role of RIF1 on EOC cells, the siRNA1-RIF1 (Si-1) and siRNA2-RIF1 (Si-2) were transfected into OVCAR3 and A2780 cells. After transfection for 48 hours, the expression of RIF1 was confirmed by RT-PCR and Western blot. As shown in Fig. 2A and 2B, RIF1-siRNAs could effectively decrease RIF1 expression in OVCAR3 and A2780 cells, respectively, as compared with scrambled control siRNA (Scr) groups. We also established RIF1 stable knockdown cell lines using OVCAR3 cells. Fig. 2C shown these stable clones had low expression of RIF1 at both mRNA and protein levels compared with the vehicle control. (Fig. 2 *** p < 0.01, * p < 0.05)
Effect of RIF1 knockdown on cellular response to cisplatin
After knockdown of RIF1 by siRNAs, the OVCAR3 and A2780 cells were subjected to MTS assay in the absence or presence of different concentrations of cisplatin. As shown in Fig. 3 , these cells with reduced RIF1 expression were significantly more sensitive to cisplatin than the scrambled control cells with a nearly doubled relative resistance factor. (Fig. 3 ** 
Effect of RIF1 expression on cellular NER activity and UV sensitivity
Base on the observation that RIF1 expression contributed to cellular response to cisplatin, which was a DNA-damaging drug, we speculated that RIF1 might affect DNA repair activities. To test this hypothesis, we used HCR assay to analyze whether knockdown of RIF1 expression affected NER activity responsible for repair of DNA damages induced by cisplatin. For this purpose, a plasmid containing luciferase reporter was UV irradiated in order to generate DNA adducts which were confirmed by PCR analysis (Fig. 4C) . The damaged reporter plasmids were then transfected into RIF1-silenced OVCAR3 or scrambled control cells followed by analysis of luciferase activity. We also used XPA-suppressed OVCAR3 cells as NER-deficient control. The luciferase activity decreased with the enhancive DNA damages due to higher doses of UV irradiation, as shown in Fig. 4D . Furthermore, the luciferase activity in OVCAR3 cells with RIF1 or XPA knockdown had no significant difference, but they were both significantly lower than the control cells transfected with scrambled siRNA. These findings suggested that knockdown RIF1 expression probably suppressed cellular NER activity. We further 
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analyze UV sensitivity of RIF1-suppressed OVCAR3 cells. As showed in Fig 4E , the cell viability of RIF1 or XPA knockdown OVCAR3 cells and scrambled control cells were reduced with the increased UV irradiation after 24 h of recovery. As shown in Fig 4F, the cell viability of RIF1 knockdown OVCAR3 cells was similar to that of XPA knockdown OVCAR3 cells, but they were both significantly lower than the scrambled control cells. Besides, the cell viability of scrambled control OVCAR3 cells with UV irradiated (10 J/m 2 ) increased over time (Fig 4F) . But the cell viability of RIF1 or XPA knockdown OVCAR3 cells barely rose along the repair time compared with the scrambled control cell. These experiments indicated that silencing of RIF1 in OVCAR3 cells suppressed its repair ability under UV irradiation, which corroborated with the results of HCR assay.
Effect of RIF1 expression on NER proteins level
Because of the findings that knockdown RIF1 expression suppressed cellular NER activity, we hypothesized that RIF1 might regulate the expression of the proteins which were important for NER pathway. To test this hypothesis, we detected whether RIF1 knockdown affected the expression of NER proteins including RPA70, RPA32, XPA and ERCC1 using RIF1-silenced OVCAR3 and A2780 cells, as well as RIF1 stable knockdown OVCAR3 cells. As shown in Fig. 5A , 5B and 5C, the protein levels of RPA70, RPA32, XPA and ERCC1 were all decreased in these cells with RIF1 knockdown compared with the control cells. Thus, we concluded that RIF1 probably regulated NER proteins including RPA70, RPA32, XPA and ERCC1, which in turn, regulated the NER activity and cellular responses to cisplatin.
Silencing of RIF1 enhanced cisplatin-induced apoptosis signaling pathway
To further assess the effect of RIF1 on the sensitivity of ovarian cells to chemotherapy, we examined the proteins expression of apoptosis signaling pathway. RIF1-silenced and scrambled control OVCAR3 cells were treated with cisplatin (0, 5 and 10 μM) for 48 h, and Western blot analysis was implemented to investigate the expression levels of cleaved PARP, PARP, Bax, Bcl2 and cleaved caspase3 and caspase3 which are important for cell apoptosis. The β-actin was used as control. As showed in Fig.6 A, we observed upregulation of cleaved PARP, cleaved Caspase3 and Bax and downregulation of Bcl2. We further calculated the ratio of Cleaved PARP/PARP, Cleaved Caspase3/Caspase3 and Bax/Bcl2 for each treatment Fig. 7A and  7B ). Moreover, RIF1 knockdown significantly inhibited the growth of xenografts (Fig. 7C) . These results together indicated that knockdown of RIF1 increased cisplatin sensitivity in vivo.
Discussion
In the current study, for the first time, we found that RIF1 was highly expressed in chemoresistant EOC patients with platinum-based chemotherapy compared with the chemosensitive EOC patients, and overexpression of RIF1 mRNA level was associated with poor prognosis of EOC patients who received platinum-based chemotherapy. We discovered that RIF1 affected the chemosensitivity to cisplatin of EOC cells in vitro and in vivo. We further demonstrated that RIF1 regulated the protein expression of apoptosis signaling and NER pathway and then mediated the NER activities and cellular response to cisplatin.
Platinum analogues remain first-line therapy of various cancers including lung, bladder, cervical, testicular and ovarian cancers [41, 42] . However, resistance is the major barrier for successful chemotherapy. Thus, it's extremely essential to predict drug response before the initiation of chemotherapy, which may contribute to choosing the most appropriate treatment strategies for patients. In our study, we demonstrated that RIF1 expression was correlated with chemosensitivity and prognosis of EOC patients based on platinum therapy and RIF1 regulated the response to cisplatin in vitro and vivo, which indicated that RIF1 might serve as a newly biomarker predicting patient drug response and prognosis. We speculate that assessing RIF1 level may be helpful for the individualized treatment for EOC patients. Because cisplatin is also a major anticancer drug for many other cancers, it is surmisable 
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Cellular Physiology and Biochemistry that RIF1 may affect cisplatin chemosensitivity and serve as a prognostic marker in other cancer patients. RIF1 has been reported to play a significant role in DNA double-strand break (DSB) repair [43, 44] . RIF1 acts downstream of 53BP1, suppressing the 5' end resection of broken DNA ends, which in turn, promoting the non-homologous end joining (NHEJ) repair and preventing homology directed repair [28, 31, [45] [46] [47] . And RIF1 can stabilize DNA ends and contribute to the repair of breaks through simple relegation [48, 49] . However, little is known about whether RIF1 participates in the DNA single-strand break (SSB). In our research, we found that RIF1 could regulate NER pathway, which is the major mechanism to repair SSB. Deletion of RIF1 could decrease the expression of NER proteins such as ERCC1, XPA, RPA70 and RPA32 and then inhibited the NER activity, leading to the defect in DNA repair and sensitivity to cisplatin. NER mechanism has been illustrated as the most primary way to repair DNA damages induced by platinum analogues among several known DNA repair pathways [11] [12] [13] . It has been found that the overexpression of ERCC1 and XPA are directly related to clinical resistance to platinum compounds therapy in human ovarian cancer [17] and the deletion of XPA or ERCC1 could sensitize the prostate cancer cells to cisplatin [50] . XPA level was also related to platinum resistance in non-small cell lung cancer [51] . The increased expression level of RPA70 and RPA32 reduced chemosensitivity of lung cancer cells to cisplatin, while decreased expression level of these proteins enhanced chemosensitivity [12] . Our results are consistent with the previous reported studies. However, the explicit mechanisms of how RIF1 interacts with the NER proteins need further exploration. It's the first time to discover that RIF1 also contributes to NER pathway, which orients a new direction for further investigation of the function of RIF1.
The NER process repairs the cisplatin DNA damage, eliminates the cytotoxic effect of cisplatin and decreases cisplatin-induced apoptosis signaling activation. Moreover, our previous study [52] found that silencing RIF1 increased cisplatin-induced apoptosis in human cervical cancer cells. Hence, it is possible that RIF1 knockdown potentiated ovarian cancer cells to platinum-based cancer treatment by disrupting the NER activity followed by increasing the apoptosis event. So we explored that whether RIF1 affects cisplatin-induced activation of apoptosis signaling in ovarian cancer. Consistently, we observed upregulation of cleaved PARP, cleaved Caspase3 and Bax and downregulation of Bcl2 in RIF1-suppressed OVCAR3 cells, indicating that knockdown of RIF1 promotes cisplatin-induced apoptosis signaling pathway. Our results are consistent with the results in the previous research performed by Wang et al [32] .. Moreover, Accumulating evidence [30] demonstrates that RIF1 plays a critical role in DNA repair and the maintenance of genomic integrity which means that RIF1-silenced cells are more fragile to external stimuli. However, RIF1 has been reported to participate in NHEJ repair which is error-prone thus leading to mutation accumulation. In the initiation of cancer, although RIF1 could repair DNA damage, mutation may be accumulated gradually. After tumorigenesis, RIF1 may be an effective therapeutic target because suppressing RIF1 could inhibit the repair capacity of cancer cells to chemotherapeutic agents and promote apoptosis of cancer cells induced by chemotherapy.
In summary, we showed that RIF1 expression level is correlated with responses of EOC patients to platinum-based chemotherapy and their survival. We also demonstrated that silencing of RIF1 sensitized EOC cellular response to cisplatin both in vitro and in vivo. Besides, for the first time, we found RIF1 may regulate the expression of NER proteins, which in turn, influence cellular NER activity and the sensitivity of cisplatin. Furthermore, knockdown of RIF1 promoted the activation of cisplatin-induced apoptosis signaling. Our study indicated that RIF1 may serve as a novel biomarker for predicting platinum-based chemosensitivity and the survival of EOC patients.
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